- Home
- EDHL vs KYTX Comparison
EDHL vs KYTX Comparison
Compare EDHL & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDHL
- KYTX
- Stock Information
- Founded
- EDHL 2021
- KYTX 2018
- Country
- EDHL Hong Kong
- KYTX United States
- Employees
- EDHL N/A
- KYTX N/A
- Industry
- EDHL
- KYTX
- Sector
- EDHL
- KYTX
- Exchange
- EDHL NYSE
- KYTX NYSE
- Market Cap
- EDHL 137.6M
- KYTX 150.0M
- IPO Year
- EDHL 2025
- KYTX 2024
- Fundamental
- Price
- EDHL $6.00
- KYTX $2.81
- Analyst Decision
- EDHL
- KYTX Strong Buy
- Analyst Count
- EDHL 0
- KYTX 5
- Target Price
- EDHL N/A
- KYTX $19.00
- AVG Volume (30 Days)
- EDHL 1.1M
- KYTX 627.6K
- Earning Date
- EDHL 01-01-0001
- KYTX 08-11-2025
- Dividend Yield
- EDHL N/A
- KYTX N/A
- EPS Growth
- EDHL N/A
- KYTX N/A
- EPS
- EDHL 0.14
- KYTX N/A
- Revenue
- EDHL $2,761,798.00
- KYTX N/A
- Revenue This Year
- EDHL N/A
- KYTX N/A
- Revenue Next Year
- EDHL N/A
- KYTX N/A
- P/E Ratio
- EDHL $42.85
- KYTX N/A
- Revenue Growth
- EDHL N/A
- KYTX N/A
- 52 Week Low
- EDHL $3.51
- KYTX $1.78
- 52 Week High
- EDHL $6.66
- KYTX $11.40
- Technical
- Relative Strength Index (RSI)
- EDHL N/A
- KYTX 46.73
- Support Level
- EDHL N/A
- KYTX $2.71
- Resistance Level
- EDHL N/A
- KYTX $3.75
- Average True Range (ATR)
- EDHL 0.00
- KYTX 0.31
- MACD
- EDHL 0.00
- KYTX -0.08
- Stochastic Oscillator
- EDHL 0.00
- KYTX 9.62
About EDHL EVERBRIGHT DIGITAL HOLDING
Everbright Digital Holding Ltd is an integrated marketing solutions provider in Hong Kong that is involved in the metaverse and related technologies, and is providing one-stop digital marketing services for the process of enterprise development. Its digital marketing solutions include metaverse stimulation, virtual reality (VR) and augmented reality (AR) design and creation, creative event planning and management, IP character creation and social media marketing.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.